Form 4: Enliven Therapeutics CSO Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Scientific Officer, Joseph P Lyssikatos, sold 20,000 shares of common stock on January 20, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (ELVN), disposed of a total of 20,000 shares of common stock.
• The sales occurred on January 20, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Lyssikatos on November 15, 2024.
• The first block of 5,491 shares was sold at a weighted average price of $26.373 per share.
• The second block of 14,509 shares was sold at a weighted average price of $26.8995 per share.
• Following these transactions, Mr. Lyssikatos beneficially owns 745,188 shares of Enliven Therapeutics common stock.
• The shares are held indirectly by The Lyssikatos Revocable Trust 12/15/2011, for which Mr. Lyssikatos serves as trustee.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale under a Rule 10b5-1 plan, which is a routine event for executives and does not inherently signal a positive or negative outlook on the company's future performance. It's a neutral event from a sentiment perspective, primarily for personal financial management.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating transparency and adherence to insider trading regulations.
• The weighted average sale prices of $26.373 and $26.8995 reflect a relatively strong valuation for the shares at the time of the transaction.

Negatives

• Insider selling, even when pre-planned, reduces the direct ownership stake of a key executive, which can sometimes be viewed with caution by investors.

Future Outlook

This filing, a Form 4, primarily reports an insider transaction and does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 trading plans, are a common occurrence in publicly traded companies across all industries. These plans allow executives to sell shares over a predetermined period to manage personal finances while avoiding accusations of trading on material non-public information. This filing is a routine disclosure within the biotech and pharmaceutical industry, where executive compensation often includes significant equity components.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider sales is a standard corporate governance practice, aligning with best practices for executive share dispositions in the U.S. market.
• The disclosure format and content are consistent with SEC requirements for Form 4 filings, comparable to similar reports from executives at peer biotechnology companies.

Stakeholder Impact

• Shareholders may note a reduction in direct insider ownership, though the pre-planned nature of the sale mitigates concerns about immediate market sentiment.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a Rule 10b5-1 trading plan, adopted well in advance. Such pre-scheduled sales are typically for personal financial management and do not reflect a change in the company's fundamental outlook or performance. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is maintained pending further material developments.

Keywords

Enliven Therapeutics, ELVN, Joseph P Lyssikatos, Insider Sale, Form 4, 10b5-1 Plan, Common Stock, Officer Transaction